Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285141 | 0.98 | LMNA (0.64) | LMNATSHRHPGDHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL11262444 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL9636052 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL13570450 | 0.96 | TSHR (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL7761655 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL11337153 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL7761593 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL6245920 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL9636042 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 | |
| SCHEMBL28461971 | 0.96 | LMNA (0.62) | LMNATSHRHPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20090035315-A1 | Method of Improving Treatments in Rheumatic and Arthritic Diseases | OSTEOLOGIX A/S (DK) | 2009-02-05 | — | — | US | claimed |
| US-20080317849-A1 | Method for Improving the Medical Treatment of Pain | OSTEOLOGIX A/S (DK) | 2008-12-25 | — | — | US | claimed |
| WO-2007149815-A1 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING ARTHRITIC AND OR OSTEOPORITIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | claimed |
| WO-2007149816-A2 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING OSTEOPOROTIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070292535-A1 | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | TRX PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | claimed |
| US-20070292529-A1 | Strontium compositions and methods of treating osteoporotic conditions | TRX PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | claimed |
| EP-1758652-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123098-A2 | PREVENTING GASTROINTESTINAL SIDE-EFFECTS WITH STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| US-20240060997-A1 | Blood Preparation and Profiling | SANGUI BIO PTY LTD (AU) | 2024-02-22 | — | — | US | disclosed |
| US-11693006-B2 | Blood profiling with protease inhibitors | SANGUI BIO PTY. LTD (AU) | 2023-07-04 | — | — | US | disclosed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | LMNA 4376/4885TSHR 4340/4885HPGD 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.